New York Oncology Hematology is a prominent name in the Health Care industry, offering world-class cancer care across multiple locations in the New York region. Established in 1985, the company has positioned itself as the largest provider of cancer and blood disorder treatment, with an extensive team comprising 35 physicians and 350 cancer care specialists. Emphasizing a patient-centric approach, they deliver expert care in a safe and convenient community-based setting. Notably, their comprehensive services encompass clinical research trial programs, stem cell transplant treatment, and hereditary cancer risk assessment, setting them apart as a leader in cancer treatment. The company's affiliation with every major hospital and participation in The US Oncology Network reflects its pivotal role in advancing cancer research and development, contributing to the approval of 50 FDA-approved cancer drugs. With a strong emphasis on innovation and patient outcomes, New York Oncology Hematology presents an attractive proposition for potential investors seeking opportunities in the healthcare sector.
There is no investment information
No recent news or press coverage available for New York Oncology Hematology.